Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LPD008
MIFTS: 58

Lipid Metabolism Disorder

Categories: Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lipid Metabolism Disorder

About this section

MalaCards integrated aliases for Lipid Metabolism Disorder:

Name: Lipid Metabolism Disorder 12 15
Disorder of Fatty Acid Metabolism 29 73
Abnormality of Lipid Metabolism 29 6
Lipid Metabolism Disorders 43 73
Dyslipidemia 12 55
Lipid Metabolism, Inborn Errors 44
Fatty Acid Metabolism Disorder 12
Dyslipidemias 73

Classifications:

MalaCards categories:
Global: Metabolic diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:3146
MeSH 44 D008052
ICD10 33 E71.3
Sources

Summaries for Lipid Metabolism Disorder

About this section
MedlinePlus : 43 Metabolism is the process your body uses to make energy from the food you eat. Food is made up of proteins, carbohydrates, and fats. Chemicals in your digestive system (enzymes) break the food parts down into sugars and acids, your body's fuel. Your body can use this fuel right away, or it can store the energy in your body tissues. If you have a metabolic disorder, something goes wrong with this process. Lipid metabolism disorders, such as Gaucher disease and Tay-Sachs disease, involve lipids. Lipids are fats or fat-like substances. They include oils, fatty acids, waxes, and cholesterol. If you have one of these disorders, you may not have enough enzymes to break down lipids. Or the enzymes may not work properly and your body can't convert the fats into energy. They cause a harmful amount of lipids to build up in your body. Over time, that can damage your cells and tissues, especially in the brain, peripheral nervous system, liver, spleen, and bone marrow. Many of these disorders can be very serious, or sometimes even fatal. These disorders are inherited. Newborn babies get screened for some of them, using blood tests. If there is a family history of one of these disorders, parents can get genetic testing to see whether they carry the gene. Other genetic tests can tell whether the fetus has the disorder or carries the gene for the disorder. Enzyme replacement therapies can help with a few of these disorders. For others, there is no treatment. Medicines, blood transfusions, and other procedures may help with complications.

MalaCards based summary : Lipid Metabolism Disorder, also known as disorder of fatty acid metabolism, is related to chylomicron retention disease and familial lipoprotein lipase deficiency. An important gene associated with Lipid Metabolism Disorder is FADS1 (Fatty Acid Desaturase 1
The expression of FADS,and its lncRNA,reverse D5-desaturase,were found to be reciprocally regulated by the dietary fat content in animal models
Dysfunction Pattern: Expression [differentially expressed]), and among its related pathways/superpathways are Metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Simvastatin and Fenofibrate have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and endothelial, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Disease Ontology : 12 An inherited metabolic disorder that involves the creation and degradation of lipids.

Wikipedia : 76 Lipid metabolism is the synthesis and degradation of lipids in cells, involving the break down or... more...

Sources

Related Diseases for Lipid Metabolism Disorder

About this section

Diseases related to Lipid Metabolism Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
# Related Disease Score Top Affiliating Genes
1 chylomicron retention disease 32.0 APOA1 APOB MTTP
2 familial lipoprotein lipase deficiency 31.9 APOA5 LIPC LPL
3 sitosterolemia 31.9 APOB HMGCR MTTP
4 lipodystrophy, familial partial, type 2 31.9 INS LEP
5 hyperlipoproteinemia, type v 31.8 APOA5 APOE INS LPL
6 prediabetes syndrome 30.9 ADIPOQ APOB COG2 CRP INS LEP
7 hypoalphalipoproteinemia, primary 30.9 APOA1 APOB APOC3 CETP LIPC LPL
8 hypolipoproteinemia 30.8 APOA1 APOB APOE LPA LPL MTTP
9 hyperlipoproteinemia, type iv 30.6 APOA1 APOA5 APOB APOC3 APOE LIPC
10 kidney disease 29.5 APOE CRP INS LPA RBP4
11 familial hyperlipidemia 29.5 APOA1 APOB APOE CETP COG2 HMGCR
12 ischemic heart disease 29.5 APOA1 APOB APOE CRP INS LPL
13 hyperlipoproteinemia, type iii 29.4 APOA1 APOA5 APOB APOE CETP COG2
14 heart disease 27.7 ADIPOQ APOA1 APOA5 APOB APOC3 APOE
15 coronary heart disease 1 25.3 ADIPOQ APOA1 APOA5 APOB APOC3 APOE
16 diabetes mellitus, noninsulin-dependent 24.5 ADIPOQ APOA1 APOB APOC3 APOE CETP
17 citrullinemia, type ii, neonatal-onset 11.6
18 fatty liver disease, nonalcoholic 1 11.3
19 aromatase deficiency 11.0
20 bietti crystalline corneoretinal dystrophy 10.8
21 xanthoma disseminatum 10.8 APOB APOE
22 acyl-coa dehydrogenase, medium-chain, deficiency of 10.8
23 acyl-coa dehydrogenase, short-chain, deficiency of 10.8
24 acyl-coa dehydrogenase, very long-chain, deficiency of 10.8
25 carnitine palmitoyltransferase i deficiency 10.8
26 tay-sachs disease 10.8
27 barth syndrome 10.8
28 carnitine palmitoyltransferase ii deficiency, infantile 10.8
29 steroid inherited metabolic disorder 10.8
30 gaucher's disease 10.8
31 malignant otitis externa 10.8 CRP INS
32 gallbladder disease 1 10.8
33 lipodystrophy, familial partial, type 3 10.8
34 lipodystrophy, familial partial, type 6 10.8
35 acquired generalized lipodystrophy 10.8 ADIPOQ LEP
36 hypercholesterolemia, autosomal dominant, type b 10.7 APOB APOE
37 familial lcat deficiency 10.7 APOA1 APOE
38 nonalcoholic steatohepatitis 10.7 ADIPOQ INS LEP
39 defective apolipoprotein b-100 10.7 APOB APOE HMGCR
40 bardet-biedl syndrome 2 10.7 APOA1 APOC3 LPL
41 endocrine pancreas disease 10.6 ADIPOQ INS LEP
42 lipase deficiency, combined 10.6 LIPC LPL
43 obesity-hypoventilation syndrome 10.6 ADIPOQ LEP
44 severe pre-eclampsia 10.6 ADIPOQ LEP RBP4
45 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.6 CRP INS LEP
46 familial partial lipodystrophy 10.6 INS LEP PPARG
47 fetal macrosomia 10.6 APOA1 APOB INS LEP
48 idiopathic recurrent pericarditis 10.5 ADIPOQ LEP
49 pancreas disease 10.5 CRP INS LEP
50 idiopathic edema 10.5 ADIPOQ INS PPARA PPARG

Comorbidity relations with Lipid Metabolism Disorder via Phenotypic Disease Network (PDN):


Chronic Myocardial Ischemia Hypertension, Essential
Intermediate Coronary Syndrome Ischemic Heart Disease

Graphical network of the top 20 diseases related to Lipid Metabolism Disorder:



Diseases related to Lipid Metabolism Disorder
Sources

Symptoms & Phenotypes for Lipid Metabolism Disorder

About this section

GenomeRNAi Phenotypes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.65 APOA1 APOA5 APOB APOC3 APOE CETP
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE LPL

MGI Mouse Phenotypes related to Lipid Metabolism Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.21 LEP APOE ADIPOQ CRP APOA1 INS
2 homeostasis/metabolism MP:0005376 10.19 ADIPOQ COG2 CRP FADS1 APOA1 HMGCR
3 cellular MP:0005384 10.14 APOE ADIPOQ FADS1 APOA1 INS APOB
4 growth/size/body region MP:0005378 10.06 APOE COG2 ADIPOQ HMGCR INS APOB
5 endocrine/exocrine gland MP:0005379 10.02 LEP APOE ADIPOQ FADS1 APOA1 INS
6 adipose tissue MP:0005375 10 LEP APOE ADIPOQ INS PPARG LPL
7 integument MP:0010771 9.76 APOE ADIPOQ APOA1 INS LEP PPARG
8 liver/biliary system MP:0005370 9.7 APOE ADIPOQ APOA1 HMGCR INS APOB
9 muscle MP:0005369 9.28 LEP APOE ADIPOQ INS APOB PPARG
Sources

Drugs & Therapeutics for Lipid Metabolism Disorder

About this section

Drugs for Lipid Metabolism Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 645)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
2
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 49562-28-9 3339
3
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 163222-33-1 150311
4
Cilostazol Approved, Investigational Phase 4,Phase 1 73963-72-1 2754
5
Probucol Approved, Investigational Phase 4,Phase 3 23288-49-5 4912
6
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
7
Fluvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 93957-54-1 1548972
8
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
9
Ciprofibrate Approved, Investigational Phase 4 52214-84-3 2763
10
Thrombin Approved, Investigational Phase 4
11
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
12
Pravastatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 81093-37-0 54687
13
Saxagliptin Approved Phase 4 361442-04-8 11243969
14
Abacavir Approved, Investigational Phase 4,Phase 2,Not Applicable 136470-78-5 65140 441300
15
Lamivudine Approved, Investigational Phase 4,Phase 2 134678-17-4 60825
16
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155213-67-5 392622
17
Lopinavir Approved Phase 4,Phase 2,Phase 1,Not Applicable 192725-17-0 92727
18
Nevirapine Approved Phase 4,Phase 2,Not Applicable 129618-40-2 4463
19
Zidovudine Approved Phase 4,Phase 2 30516-87-1 35370
20
Pitavastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147511-69-1, 147526-32-7 6366718 5282452
21
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1 88150-42-9 2162
22
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
23
Lovastatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75330-75-5 53232
24
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 22916-47-8 4189
25
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 128794-94-5 5281078
26
Mycophenolic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 24280-93-1 446541
27
Bezafibrate Approved, Investigational Phase 4,Phase 3,Phase 2 41859-67-0 39042
28
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
29
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 154598-52-4 64139
30
Darunavir Approved Phase 4,Phase 1 635728-49-3, 206361-99-1 213039
31
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 144701-48-4 65999
32 Fenofibric acid Approved Phase 4,Phase 3,Phase 1,Not Applicable 42017-89-0
33
Gemfibrozil Approved Phase 4,Phase 1 25812-30-0 3463
34
Hydroxocobalamin Approved Phase 4,Phase 1,Phase 2 13422-51-0 11953898 44475014
35
Emtricitabine Approved, Investigational Phase 4,Not Applicable 143491-57-0 60877
36
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
37
Loperamide Approved Phase 4,Not Applicable 53179-11-6 3955
38
Colestipol Approved Phase 4 26658-42-4
39
Everolimus Approved Phase 4,Phase 1 159351-69-6 6442177
40
Sirolimus Approved, Investigational Phase 4,Phase 1 53123-88-9 5284616 6436030 46835353
41
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 1 137862-53-4 60846
42
Acarbose Approved, Investigational Phase 4,Phase 3 56180-94-0 441184
43
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
44
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 122320-73-4 77999
45
Coal tar Approved Phase 4,Phase 2,Phase 1,Not Applicable 8007-45-2
46
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
47
Mannitol Approved, Investigational Phase 4,Not Applicable,Early Phase 1 69-65-8 453 6251
48
Heparin Approved, Investigational Phase 4,Not Applicable 9005-49-6 772 46507594
49
Bexarotene Approved, Investigational Phase 4 153559-49-0 82146
50
Exenatide Approved, Investigational Phase 4,Not Applicable 141758-74-9 15991534

Interventional clinical trials:

(show top 50) (show all 2562)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin Unknown status NCT01613729 Phase 4 Rosuvastatin 5 mg;Rosuvastatin 10 mg
2 An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin Unknown status NCT00678743 Phase 4 Omacor + simvastatin
3 Nutraceuticals to Improve Lipid Profile in European Countries Unknown status NCT01649986 Phase 4 Nutraceuticals (Armolipid Plus)
4 Treatment of Hyperlipidemia and Sexual Dysfunction Unknown status NCT00923676 Phase 4 fenofibrate;Rosuvastatin;fenofibrate + rosuvastatin
5 Effectiveness of Treatment of Hypercholesterolemia With Rosuvastatin and Ezetimibe Unknown status NCT02772640 Phase 4 Rosuvastatin and Ezetimibe morning or evening administration
6 To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Unknown status NCT02098460 Phase 4 Atorvastatin, Probucol, Cilostazol
7 Probiotic BIO-25 as a Supplement to Statins for the Treatment of Hypercholesterolemia Unknown status NCT01849185 Phase 4
8 Lovaza Mechanisms of Action Unknown status NCT01301794 Phase 4
9 Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia Unknown status NCT00972829 Phase 4 Rosuvastatin;Ezetimibe
10 Triglyceride Lowering Study Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
11 Trial to Assess the Effects of P-OM3 on LDL-C in Subjects With Primary Hypercholesterolemia Unknown status NCT00746811 Phase 4 P-OM3;Placebo
12 Fluvastatin After Heart Transplantation Unknown status NCT00421005 Phase 4 fluvastatin
13 Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy? Unknown status NCT00295373 Phase 4 Rosuvastatin
14 Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia Unknown status NCT01010516 Phase 4 High-dose rosuvastatin;Statin plus fenofibrate;Statin plus niacin ER/laropiprant
15 Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
16 Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study) Unknown status NCT02035644 Phase 4 Jinlida granules;placebo granules
17 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
18 Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
19 The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients Unknown status NCT00758927 Phase 4 Omega-3 acid 4 grams per day;Placebo control
20 Japanese Primary Prevention Project With Aspirin Unknown status NCT00225849 Phase 4 Aspirin
21 Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia Unknown status NCT01480687 Phase 4 Ciprofibrate
22 Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes Unknown status NCT01322711 Phase 4 Atorvastatin;Placebo
23 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
24 The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
25 Effect of Rosuvastatin Therapy on HDL2 Level Unknown status NCT02593487 Phase 4 Rosuvastatin 10mg/d group;Rosuvastatin 20mg/d group
26 Effect of Nasal CPAP on Lipid Profile in Patients With Dyslipidaemia and Sleep Apnea Unknown status NCT02557412 Phase 4
27 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients Unknown status NCT00135460 Phase 4 nucleoside analogue sparing HAART regimen
28 Effects of DPP-4 Inhibition on Triglycerides Unknown status NCT01527747 Phase 4 Saxagliptin
29 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Unknown status NCT01382277 Phase 4 Rosuvastatin
30 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT) Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
31 Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH) Unknown status NCT00885872 Phase 4 Rosuvastatin (Crestor)
32 Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Unknown status NCT00843661 Phase 4 ezetimibe;fenofibrate;pravastatin
33 Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease Unknown status NCT00487630 Phase 4 recombinant alpha-galactosidase A
34 A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
35 SHARE: Simple HAART With Abacavir, Reyataz, and Epivir Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
36 The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control Unknown status NCT00282659 Phase 4 magnesium L-lactate
37 Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
38 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
39 Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED) Completed NCT00651963 Phase 4 ezetimibe
40 Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia Completed NCT01551173 Phase 4 Fluvastatin sodium
41 Pharmacological Regulation of Fat Transport in Metabolic Syndrome Completed NCT00632840 Phase 4 Atorvastatin and fenofibrate
42 Regulation of Lipoprotein Transport in Metabolic Syndrome Completed NCT00841217 Phase 4 GW501516;placebo pill
43 Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes Completed NCT02689765 Phase 4
44 Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study Completed NCT00701727 Phase 4 ezetimibe;Placebo
45 Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects Completed NCT01385020 Phase 4 Gemfibrozil & red yeast rice (LipoCol)
46 Effect of Polyvitaminics (Pyridoxine Hydrochloride, Folic Acid and Cyanocobalamin) in the Concentration of Homocysteine and Lipid Profile in Postmenopausal Women: a Randomized Controlled, Double-blind Clinical Trial Completed NCT03221816 Phase 4 Tenavit®;Placebo Oral Tablet
47 Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) Completed NCT02642159 Phase 4 Alirocumab;Statins;Ezetimibe;Fenofibrate;Nicotinic acid;Omega-3 fatty acids;Antihyperglycemic Drug
48 Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir Completed NCT02442700 Phase 4 pitavastatin;placebo
49 The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients Completed NCT02103049 Phase 4 Ezetimibe
50 A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia Completed NCT02057302 Phase 4 Xuezhikang capsule

Search NIH Clinical Center for Lipid Metabolism Disorder

Cochrane evidence based reviews: lipid metabolism, inborn errors

Sources

Genetic Tests for Lipid Metabolism Disorder

About this section

Genetic tests related to Lipid Metabolism Disorder:

# Genetic test Affiliating Genes
1 Disorder of Fatty Acid Metabolism 29
2 Abnormality of Lipid Metabolism 29
Sources

Anatomical Context for Lipid Metabolism Disorder

About this section

MalaCards organs/tissues related to Lipid Metabolism Disorder:

41
Heart, Liver, Endothelial, Testes, Bone, Kidney, Bone Marrow
Sources

Publications for Lipid Metabolism Disorder

About this section

Articles related to Lipid Metabolism Disorder:

(show all 38)
# Title Authors Year
1
Polystyrene microplastics induce gut microbiota dysbiosis and hepatic lipid metabolism disorder in mice. ( 29529433 )
2018
2
Curcumin Attenuates Lipopolysaccharide-Induced Hepatic Lipid Metabolism Disorder by Modification of m<sup>6</sup> A RNA Methylation in Piglets. ( 29488640 )
2018
3
Magnesium isoglycyrrhizinate blocks fructose-induced hepatic NF-I_B/NLRP3 inflammasome activation and lipid metabolism disorder. ( 28526339 )
2017
4
Protective effects of allicin on 1,3-DCP-induced lipid metabolism disorder in HepG2 cells. ( 29169723 )
2017
5
Association of SREBP2 gene polymorphisms with the risk of osteonecrosis of the femoral head relates to gene expression and lipid metabolism disorders. ( 28901487 )
2017
6
HNF-4I+ regulated miR-122 contributes to development of gluconeogenesis and lipid metabolism disorders in Type 2 diabetic mice and in palmitate-treated HepG2 cells. ( 27592052 )
2016
7
Higher PDCD4 expression is associated with obesity, insulin resistance, lipid metabolism disorders, and granulosa cell apoptosis in polycystic ovary syndrome. ( 26868993 )
2016
8
Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4I+ miR122 Pathway. ( 27011261 )
2016
9
Oral tributyrin prevents endotoxin-induced lipid metabolism disorder. ( 28531464 )
2015
10
Angelica sinensis polysaccharide regulates glucose and lipid metabolism disorder in prediabetic and streptozotocin-induced diabetic mice through the elevation of glycogen levels and reduction of inflammatory factors. ( 25630053 )
2015
11
L-Carnitine intake prevents irregular feeding-induced obesity and lipid metabolism disorder. ( 25445284 )
2015
12
Yhhu981, a novel compound, stimulates fatty acid oxidation via the activation of AMPK and ameliorates lipid metabolism disorder in ob/ob mice. ( 25732571 )
2015
13
Oral Exposure of Mice to Carbendazim Induces Hepatic Lipid Metabolism Disorder and Gut Microbiota Dysbiosis. ( 26071454 )
2015
14
Effect of Hypericum perforatum L. extract on insulin resistance and lipid metabolic disorder in high-fat-diet induced obese mice. ( 25266458 )
2015
15
[Genetically determined lipid metabolism disorders due to oral intake of technogenic hyperchlorination products]. ( 26596112 )
2015
16
Danqi Pill regulates lipid metabolism disorder induced by myocardial ischemia through FATP-CPTI pathway. ( 25885422 )
2015
17
Green tea extract containing a highly absorbent catechin prevents diet-induced lipid metabolism disorder. ( 24067358 )
2013
18
Ameliorating effect of mother tincture of Syzygium jambolanum on carbohydrate and lipid metabolic disorders in streptozotocin-induced diabetic rat: Homeopathic remedy. ( 23633838 )
2013
19
Quercetin Protects against Cadmium-Induced Renal Uric Acid Transport System Alteration and Lipid Metabolism Disorder in Rats. ( 22690247 )
2012
20
Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy. ( 22213519 )
2012
21
Abnormal barrier function in the pathogenesis of ichthyosis: therapeutic implications for lipid metabolic disorders. ( 22507046 )
2012
22
The model of rat lipid metabolism disorder induced by chronic stress accompanying high-fat-diet. ( 21871127 )
2011
23
[The role of lipid metabolism disorders in kidney disease in metabolic syndrome associated with obesity]. ( 21961334 )
2011
24
Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein. ( 21093950 )
2011
25
Fat and cholesterol diet induced lipid metabolic disorders and insulin resistance in rabbit. ( 19301228 )
2009
26
Chanarin-Dorfman syndrome: clinical features of a rare lipid metabolism disorder. ( 19250403 )
2009
27
[Analysis of SNPs and enzymatic disorder in the patients of influenza-associated encephalopathy: disorder of fatty acid metabolism in mitochondria induced by high fever]. ( 17037363 )
2006
28
Is autism a disorder of fatty acid metabolism? Possible dysfunction of mitochondrial beta-oxidation by long chain acyl-CoA dehydrogenase. ( 15142659 )
2004
29
[Carbohydrate and lipid metabolism disorders in obese children and adolescents]. ( 15858253 )
2004
30
[Interconnection between insulin resistance and lipid metabolism disorders in obese patients]. ( 12469622 )
2002
31
[Lipid metabolic disorders in obesity: their epidemiology, physiopathology and clinico-therapeutic implications]. ( 9773577 )
1997
32
[Pharmacologic treatment of lipid metabolism disorders]. ( 9214849 )
1996
33
[The evaluation of a method for determining apolipoproteins as a sensitive indicator in assessing lipid metabolic disorder in a population at risk for essential arterial hypertension (EAHT)]. ( 9455355 )
1995
34
[Lipid metabolic disorders and lipid peroxidation in patients with the nephrotic syndrome]. ( 8079411 )
1994
35
[Relationship between lipid metabolism disorders and age of first manifestations of coronary heart disease]. ( 1509793 )
1992
36
[Pathophysiology and therapy of lipid metabolism disorders in kidney diseases]. ( 1921228 )
1991
37
[Restriction polymorphism in patients with lipid metabolism disorders and ischemic heart disease]. ( 1979835 )
1990
38
A lipid metabolic disorder: disseminated lipogranulomatosis; a syndrome with similarity to, and important difference from, Niemann-Pick and Hand-SchA1ller-Christian disease. ( 12975849 )
1952
Sources

Variations for Lipid Metabolism Disorder

About this section

ClinVar genetic disease variations for Lipid Metabolism Disorder:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 APOE NM_000041.3(APOE): c.461G> T (p.Arg154Leu) single nucleotide variant Likely pathogenic rs200703101 GRCh38 Chromosome 19, 44908757: 44908757
2 APOE NM_000041.3(APOE): c.461G> T (p.Arg154Leu) single nucleotide variant Likely pathogenic rs200703101 GRCh37 Chromosome 19, 45412014: 45412014
Sources

Expression for Lipid Metabolism Disorder

About this section
Search GEO for disease gene expression data for Lipid Metabolism Disorder.
Sources

Pathways for Lipid Metabolism Disorder

About this section

Pathways related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Metabolism 66
Show member pathways
 13.82 ADIPOQ APOA1 APOA5 APOB APOC3 APOE
2
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) 66
Show member pathways
 12.75 ADIPOQ APOA1 APOA5 FADS1 HMGCR LEP
3
Metabolism of water-soluble vitamins and cofactors 66
Show member pathways
 12.58 APOA1 APOB APOC3 APOE LPL RBP4
4
Glucose / Energy Metabolism 4
12.37 ADIPOQ APOE INS PPARG
5
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.36 ADIPOQ HMGCR INS LEP PPARG
6
Metabolism of fat-soluble vitamins 66
Show member pathways
 12.26 APOA1 APOB APOC3 APOE LPL RBP4
7
Folate Metabolism 1
Show member pathways
 12.24 APOA1 APOB APOE CRP INS
9
Lipoprotein metabolism 66
Show member pathways
 12.19 APOA1 APOA5 APOB APOC3 APOE CETP
10
Adipogenesis 1
11.97 ADIPOQ INS LEP LPL PPARA PPARG
11
Binding and Uptake of Ligands by Scavenger Receptors 66
Show member pathways
 11.77 APOA1 APOB APOE
12
Sterol Regulatory Element-Binding Proteins (SREBP) signalling 1
11.67 HMGCR INS LPL PPARG RBP4
13
Adipocytokine signaling pathway 37
11.58 ADIPOQ LEP PPARA
14
PPAR signaling pathway 37
11.56 ADIPOQ APOA1 APOA5 APOC3 LPL PPARA
15
Statin Pathway 1
Show member pathways
 11.44 APOA1 APOA5 APOB APOC3 APOE CETP
16
Fat digestion and absorption 37
Show member pathways
 11.38 APOA1 APOB MTTP
17
PPAR Alpha Pathway 1
11.15 APOA1 APOA5 APOC3 PPARA
18
Differentiation of white and brown adipocyte 1
11.11 ADIPOQ LEP PPARG
19
Transcription factor regulation in adipogenesis 1
11.04 ADIPOQ LEP PPARG
Sources

GO Terms for Lipid Metabolism Disorder

About this section

Cellular components related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.98 APOA1 APOA5 APOB APOE INS LIPC
2 early endosome GO:0005769 9.83 APOA1 APOB APOC3 APOE
3 extracellular matrix GO:0031012 9.81 APOA1 APOC3 APOE LPL
4 low-density lipoprotein particle GO:0034362 9.71 APOA1 APOA5 APOB APOE
5 high-density lipoprotein particle GO:0034364 9.65 APOA1 APOA5 APOE CETP LIPC
6 endocytic vesicle lumen GO:0071682 9.63 APOA1 APOB APOE
7 endosome lumen GO:0031904 9.54 APOB INS
8 spherical high-density lipoprotein particle GO:0034366 9.49 APOA1 APOC3
9 discoidal high-density lipoprotein particle GO:0034365 9.48 APOA1 APOE
10 intermediate-density lipoprotein particle GO:0034363 9.46 APOA1 APOB APOC3 APOE
11 very-low-density lipoprotein particle GO:0034361 9.43 APOA1 APOA5 APOB APOC3 APOE LPL
12 chylomicron GO:0042627 9.1 APOA1 APOA5 APOB APOC3 APOE LPL
13 extracellular region GO:0005576 10.21 ADIPOQ APOA1 APOA5 APOB APOC3 APOE
14 extracellular space GO:0005615 10.13 ADIPOQ APOA1 APOA5 APOB APOC3 APOE

Biological processes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Name GO ID Score Top Affiliating Genes
1 lipid catabolic process GO:0016042 9.99 APOB APOC3 LIPC LPL
2 response to ethanol GO:0045471 9.99 ADIPOQ HMGCR LEP RBP4
3 response to organic substance GO:0010033 9.99 APOB FADS1 INS PPARG
4 triglyceride metabolic process GO:0006641 9.99 APOA5 APOC3 APOE CETP LPL MTTP
5 response to insulin GO:0032868 9.98 FADS1 INS LEP PPARA
6 response to nutrient levels GO:0031667 9.97 ADIPOQ INS LEP PPARA
7 cholesterol efflux GO:0033344 9.97 APOA1 APOA5 APOB APOC3 APOE
8 cholesterol biosynthetic process GO:0006695 9.95 APOA1 APOA5 APOE HMGCR
9 high-density lipoprotein particle remodeling GO:0034375 9.95 APOA1 APOC3 APOE CETP LIPC
10 circadian rhythm GO:0007623 9.93 ADIPOQ LEP MTTP
11 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.93 ADIPOQ CETP CRP PPARA PPARG
12 response to glucose GO:0009749 9.92 ADIPOQ INS LPL
13 low-density lipoprotein particle remodeling GO:0034374 9.92 APOB APOE CETP LIPC LPA
14 fatty acid biosynthetic process GO:0006633 9.91 FADS1 LIPC LPL
15 glucose metabolic process GO:0006006 9.91 ADIPOQ INS LEP
16 cholesterol transport GO:0030301 9.91 APOA1 APOB CETP LIPC
17 positive regulation of lipid biosynthetic process GO:0046889 9.91 APOA1 APOA5 APOE INS
18 triglyceride homeostasis GO:0070328 9.91 APOA1 APOA5 APOC3 APOE CETP LIPC
19 phospholipid efflux GO:0033700 9.9 APOA1 APOA5 APOC3 APOE
20 phospholipid transport GO:0015914 9.89 APOA1 CETP MTTP
21 negative regulation of MAP kinase activity GO:0043407 9.89 ADIPOQ APOE HMGCR
22 lipid homeostasis GO:0055088 9.88 APOE CETP PPARG
23 chylomicron remnant clearance GO:0034382 9.88 APOB APOC3 APOE LIPC
24 chylomicron assembly GO:0034378 9.88 APOA1 APOB APOC3 APOE MTTP
25 reverse cholesterol transport GO:0043691 9.88 APOA1 APOA5 APOC3 APOE CETP LIPC
26 triglyceride catabolic process GO:0019433 9.87 APOA1 APOA5 APOB APOC3 APOE LIPC
27 lipoprotein transport GO:0042953 9.85 APOB MTTP PPARG
28 phosphatidylcholine metabolic process GO:0046470 9.85 APOA1 APOA5 CETP
29 high-density lipoprotein particle assembly GO:0034380 9.85 APOA1 APOA5 APOE
30 very-low-density lipoprotein particle assembly GO:0034379 9.84 APOB APOC3 MTTP
31 negative regulation of blood vessel diameter GO:0097756 9.84 CRP HMGCR INS
32 positive regulation of cholesterol esterification GO:0010873 9.83 APOA1 APOA5 APOE
33 neuron projection regeneration GO:0031102 9.83 APOA1 APOA5 APOE
34 chylomicron remodeling GO:0034371 9.83 APOA1 APOB APOC3 APOE LPL
35 regulation of cholesterol transport GO:0032374 9.82 APOA1 APOA5 APOE
36 regulation of Cdc42 protein signal transduction GO:0032489 9.81 APOA1 APOC3 APOE
37 lipoprotein biosynthetic process GO:0042158 9.8 APOA1 APOB APOE
38 lipoprotein metabolic process GO:0042157 9.8 APOA1 APOA5 APOB APOC3 APOE MTTP
39 lipid metabolic process GO:0006629 9.8 APOA1 APOB APOC3 APOE CETP FADS1
40 regulation of intestinal cholesterol absorption GO:0030300 9.79 APOA1 APOA5 LEP
41 negative regulation of lipid catabolic process GO:0050995 9.76 APOC3 INS
42 positive regulation of cellular protein metabolic process GO:0032270 9.76 ADIPOQ INS
43 positive regulation of insulin receptor signaling pathway GO:0046628 9.76 INS LEP
44 regulation of fat cell differentiation GO:0045598 9.76 LEP PPARG
45 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.76 APOB LPL
46 positive regulation of cholesterol efflux GO:0010875 9.76 ADIPOQ APOE
47 fatty acid oxidation GO:0019395 9.76 ADIPOQ PPARG
48 negative regulation of gluconeogenesis GO:0045721 9.75 ADIPOQ INS
49 fatty acid homeostasis GO:0055089 9.75 APOE INS
50 long-chain fatty acid transport GO:0015909 9.75 APOE PPARG

Molecular functions related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 phospholipid binding GO:0005543 9.85 APOA1 APOA5 APOB APOC3 APOE
2 heparin binding GO:0008201 9.85 APOA5 APOB APOE LIPC LPA LPL
3 hormone activity GO:0005179 9.76 ADIPOQ INS LEP
4 lipid binding GO:0008289 9.76 APOA1 APOA5 APOB APOC3 APOE CETP
5 low-density lipoprotein particle receptor binding GO:0050750 9.71 APOA5 APOB APOE CRP
6 phosphatidylcholine binding GO:0031210 9.67 APOA1 APOA5 CETP
7 phospholipid transporter activity GO:0005548 9.65 APOA1 CETP MTTP
8 cholesterol binding GO:0015485 9.65 APOA1 APOA5 APOC3 APOE CETP
9 apolipoprotein binding GO:0034185 9.62 LIPC LPA LPL MTTP
10 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.61 APOA1 APOA5 APOE
11 low-density lipoprotein particle binding GO:0030169 9.58 CRP LIPC
12 phospholipase activity GO:0004620 9.57 LIPC LPL
13 lipoprotein particle binding GO:0071813 9.56 APOA1 APOE
14 lipase inhibitor activity GO:0055102 9.55 APOA1 APOC3
15 lipase binding GO:0035473 9.54 APOA5 APOB
16 high-density lipoprotein particle receptor binding GO:0070653 9.52 APOA1 APOC3
17 triglyceride binding GO:0017129 9.51 CETP LPL
18 lipid transporter activity GO:0005319 9.35 APOA1 APOB APOE CETP MTTP
19 cholesterol transporter activity GO:0017127 9.02 APOA1 APOA5 APOB APOE CETP
Sources

Sources for Lipid Metabolism Disorder

About this section
3 CDC
7